Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
Covered in this story
Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.